| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10025563 | HBV | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
| TVIS30053433 | HIV | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
| TVIS30053434 | HIV | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
| TVIS20005833 | HPV | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
| TVIS20043403 | HPV | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
| TVIS44021380 | HTLV-1 | ENSG00000131069.20 | protein_coding | ACSS2 | No | No | 55902 | Q4G0E8 Q6DKJ3 Q96FY7 Q9NR19 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ACSS2 |
|---|---|
| DrugBank ID | DB00171 |
| Drug Name | ATP |
| Target ID | BE0000350 |
| UniProt ID | Q9NR19 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 12493915; 14704009 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Starai VJ, Celic I, Cole RN, Boeke JD, Escalante-Semerena JC: Sir2-dependent activation of acetyl-CoA synthetase by deacetylation of active lysine. Science. 2002 Dec 20;298(5602):2390-2.@@Schuler AJ, Jenkins D: Enhanced biological phosphorus removal from wastewater by biomass with different phosphorus contents, Part II: Anaerobic adenosine triphosphate utilization and acetate uptake rates. Water Environ Res. 2003 Nov-Dec;75(6):499-511. |
| Groups | Investigational; Nutraceutical |
| Direct Classification | Purine ribonucleoside triphosphates |
| SMILES | NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O |
| Pathways | Glycerolipid Metabolism; Fatty Acid Metabolism; Pamidronate Action Pathway; Simvastatin Action Pathway; Citric Acid Cycle; Glutamate Metabolism; Argininosuccinic Aciduria; Gluconeogenesis; Betaine Metabolism; Butyrate Metabolism; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Rosuvastatin Action Pathway; Propanoate Metabolism; Pentose Phosphate Pathway; Pyruvate Metabolism; Inositol Metabolism; Zoledronate Action Pathway; Glycine and Serine Metabolism; Selenoamino Acid Metabolism; Thiamine Metabolism; Pyrimidine Metabolism; Carbamoyl Phosphate Synthetase Deficiency; Ammonia Recycling; Histidine Metabolism; Pravastatin Action Pathway; Arginine and Proline Metabolism; Starch and Sucrose Metabolism; Purine Metabolism; Fluvastatin Action Pathway; Galactose Metabolism |
| PharmGKB | PA164743471 |
| ChEMBL | CHEMBL14249 |
